

## DIASORIN: COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS PURSUANT TO ARTICLE 85-BIS, PARAGRAPH 4-BIS, OF CONSOB REGULATION NO. 11971/1999

**Saluggia, April 16, 2024** – In accordance with Article 85-bis paragraph 4-bis, of Consob Regulation no. 11971/1999 Diasorin (FTSE MIB: DIA) hereby communicates the total amount of the voting rights, together with the number of shares making up the share capital, as of April 15, 2024 (record date):

|                                                                                                                                 | Number of<br>shares making<br>up share capital | No. of voting<br>rights | Euro       |
|---------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|-------------------------|------------|
| <b>Total amount, of which:</b>                                                                                                  | 55,948,257                                     | 88,374,352              | 55,948,257 |
| <b>Ordinary shares without<br/>increased voting rights</b><br>ISIN IT0003492391<br>(regular dividend)<br>Current coupon: no. 18 | 23,522,162                                     | 23,522,162              | -          |
| <b>Ordinary shares with<br/>increased voting rights</b><br>ISIN IT0005188385<br>(regular dividend)<br>Current coupon: no. 18    | 32,426,095                                     | 64,852,190              | -          |

### About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 35 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at [www.diasorin.com](http://www.diasorin.com)

### For additional information, please contact:

**Riccardo Fava**  
Corporate Vice President Communication & Investor Relations  
[riccardo.fava@diasorin.com](mailto:riccardo.fava@diasorin.com)

**Eugenia Ragazzo**  
Corporate Investor Relations & ESG Analyst  
[eugenia.ragazzo@diasorin.com](mailto:eugenia.ragazzo@diasorin.com)